Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review.

Sans-Pola, Carla; Danés, Immaculada; Bosch, Josep Àngel; Marrero-Álvarez, Patricia; Cortés, Josefina; Agustí, Antònia

Sans-Pola, Carla; Danés, Immaculada; Bosch, Josep Àngel; Marrero-Álvarez, Patricia; Cortés, Josefina; Agustí, Antònia.

Affiliation

Sans-Pola C; Department of Clinical Pharmacology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Danés I; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Bosch JÀ; Clinical Pharmacology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain.
Marrero-Álvarez P; Department of Clinical Pharmacology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Cortés J; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Agustí A; Clinical Pharmacology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain.

Front Med (Lausanne) ; 10: 1159794, 2023.

Article in En | MEDLINE | ID: mdl-37305139